Search - tctmd.com

Displaying 1 - 20 of 51

Sort: Relevancy | Date

News Conference News TCT 2025

At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I

Yael L. Maxwell

November 07, 2025

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Todd Neale

November 03, 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Stent’s Benefits Seen Over Time

News Conference News TCT 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Michael O'Riordan

October 29, 2025

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

Presentation TCT 2025

TCT 202: Sirolimus-Eluting Iron Bioresorbable Scaffold in Coronary Artery Disease: First Patient-Level Pooled Analysis Comprising Randomized IRONMAN-II Trial and Prospective IRONMAN-III Registry

Presenter: Lei Song

October 26, 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Conference News TCT 2023

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Michael O'Riordan

November 01, 2023

News Conference News TCT 2023

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

Caitlin E. Cox

October 27, 2023

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

Presentation TCT 2022

TCT 155: The Bioadaptor RCT Study: Comparison of a Novel Sirolimus-Eluting Bioadaptor with Zotarolimus-Eluting Stent in de novo Coronary Arteries

Presenter: Holger Nef

September 19, 2022

Presentation TCT 2022

TCT 64: FANTOM II Long Lesion Study: Initial Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold in Long Lesions – 3 Clinical Year Outcomes

Presenter: Matthias Lutz

September 17, 2022

Presentation TCT 2022

TCT 58: FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – Final: 5 Year Clinical Outcomes

Presenter: Matthias Lutz

September 17, 2022

Presentation TCT 2021

FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report: Final 5 Year Clinical Outcomes

Presenter: Matthias Lutz

November 04, 2021

News Conference News TCT 2021

OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions

L.A. McKeown

October 25, 2021

News Conference News TCT 2021

Good Long-term Results With FANTOM BVS, but More Data Needed

Michael O'Riordan

October 21, 2021

News Conference News TCT 2020

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

L.A. McKeown

October 17, 2020

News Conference News TCT 2020

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

Todd Neale

October 14, 2020

News Conference News TCT 2018

TALENT: Indian-Made Supraflex DES Stands Up Well Against Xience in All-Comers

Todd Neale

September 22, 2018

Polymer-Free BioFreedom Stent as Safe as Orsiro, but Not as Effective

News Conference News TCT 2018

CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro

Michael O'Riordan

September 22, 2018

News Opinion Editor's Corner TCT 2018

TCT 2018, Day One: ‘Back to the Future’ With Stents, Stents, and More Stents

Shelley Wood

September 22, 2018

Advertisement

At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

TCT 202: Sirolimus-Eluting Iron Bioresorbable Scaffold in Coronary Artery Disease: First Patient-Level Pooled Analysis Comprising Randomized IRONMAN-II Trial and Prospective IRONMAN-III Registry

What’s Going to Be Hot at TCT 2025

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

TCT 155: The Bioadaptor RCT Study: Comparison of a Novel Sirolimus-Eluting Bioadaptor with Zotarolimus-Eluting Stent in de novo Coronary Arteries

TCT 64: FANTOM II Long Lesion Study: Initial Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold in Long Lesions – 3 Clinical Year Outcomes

TCT 58: FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – Final: 5 Year Clinical Outcomes

FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report: Final 5 Year Clinical Outcomes

OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions

Good Long-term Results With FANTOM BVS, but More Data Needed

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

TALENT: Indian-Made Supraflex DES Stands Up Well Against Xience in All-Comers

CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro

TCT 2018, Day One: ‘Back to the Future’ With Stents, Stents, and More Stents

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content